文献速递淋巴瘤

ICOS在皮肤T细胞淋巴瘤中广泛表达,靶向ICOS可强效杀伤恶性细胞

ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.
PubMed 文献 · Blood Adv · 2020-01-01

晚期皮肤T细胞淋巴瘤(CTCL)治疗需求未满足。免疫组化显示ICOS在52例蕈样肉芽肿和Sézary综合征(SS)患者皮肤活检及SS淋巴结活检的恶性细胞中广泛表达,流式细胞术显示所有SS患者循环肿瘤细胞强表达ICOS,且SS患者ICOS+ Treg细胞比例显著高于健康供者。抗ICOS抗体药物偶联物(ADC)在3个CTCL细胞系中呈剂量依赖性降低细胞活力,在小鼠异种移植模型中体内外疗效优于brentuximab vedotin,并在ICOS+患者来源异种移植中显示疗效,为治疗试验提供初步基础。

要点

  • ICOS在蕈样肉芽肿和Sézary综合征恶性细胞及循环肿瘤细胞中广泛强表达。
  • SS患者ICOS+ Treg细胞比例显著高于健康供者。
  • 抗ICOS ADC在CTCL临床前模型中疗效优于brentuximab vedotin。

核心结论

  • ICOS在CTCL恶性细胞中广泛表达,靶向ICOS的ADC在临床前模型中显示强效杀伤恶性细胞的作用,为治疗试验提供初步基础。

研究设计与样本

  • 免疫组化分析52例蕈样肉芽肿和Sézary综合征患者皮肤活检及SS淋巴结活检标本。
  • 流式细胞术检测SS患者循环肿瘤细胞ICOS表达及ICOS+ Treg细胞比例。
  • 在3个CTCL细胞系(Myla、MJ和HUT78)中评估抗ICOS ADC的细胞活力影响。
  • 在小鼠异种移植模型(MyLa)中比较抗ICOS-MMAE ADC与brentuximab vedotin的体内外疗效。
  • 在ICOS+ SS和血管免疫母细胞性T细胞淋巴瘤患者来源异种移植中评估抗ICOS ADC疗效。

主要发现

  • 免疫组化显示ICOS在52例蕈样肉芽肿和Sézary综合征患者皮肤活检及SS淋巴结活检的恶性细胞中广泛表达。
  • 流式细胞术显示所有SS患者循环肿瘤细胞强表达ICOS。
  • SS患者ICOS+ Treg细胞比例显著高于健康供者。
  • 在3个CTCL细胞系中,抗ICOS ADC呈剂量依赖性显著降低细胞活力。
  • 在小鼠异种移植模型(MyLa)中,抗ICOS-MMAE ADC的体内外疗效优于brentuximab vedotin。

临床怎么用

  • ICOS可作为CTCL靶向治疗的潜在靶点,尤其对Sézary综合征循环肿瘤细胞和ICOS+ Treg细胞高表达患者。
  • 抗ICOS ADC在临床前模型中疗效优于brentuximab vedotin,支持开展治疗临床试验。

局限性

  • 研究为临床前阶段,尚未在患者中评估抗ICOS ADC的安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of advanced-stage cutaneous T-cell lymphoma (CTCL) remains an unmet medical need. Mogamulizumab, anti-KIR3DL2, and brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate (ADC) coupled with monomethyl-auristatin-E (MMAE), provided encouraging results, but new targeted therapies are needed. Inducible T-cell costimulator (ICOS), a T-cell costimulatory receptor, is a promising therapeutic target, not only because it is expressed by malignant T cells in CTCL but also because of its connection with the suppressive activity of regulatory T (Treg) cells. Immunohistochemical analysis revealed that ICOS was widely expressed by malignant cells in skin biopsy specimens from 52 patients with mycosis fungoides and Sézary syndrome (SS), as well as in involved node biopsy specimens from patients with SS. Furthermore, flow cytometry demonstrated its strong expression by circulating tumor cells in all our patients with SS. Percentages of ICOS+ Treg cells were significantly higher in patients with SS than in healthy donors. We then investigated the preclinical efficacy of anti-ICOS ADCs generated by coupling murine anti-ICOS monoclonal antibodies with MMAE and pyrrolobenzodiazepine. In 3 CTCL cell lines (Myla, MJ, and HUT78), we observed a significant dose-dependent decrease in cell viability in the presence of anti-ICOS ADCs. In addition, anti-ICOS-MMAE ADCs had an in vitro and in vivo efficacy superior to BV in a mouse xenograft model (MyLa). Finally, we assessed the efficacy of anti-ICOS ADCs in ICOS+ patient-derived xenografts from patients with SS and angioimmunoblastic T-cell lymphoma. Collectively, our findings provide the preliminary basis for a therapeutic trial.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Amatore F, Ortonne N, Lopez M, et al. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Adv. 2020. PMID: 33095875. doi:10.1182/bloodadvances.2020002395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。